From Concept to First-in-Human: Building the Path to Clinical Validation
Bringing a medical device from an early concept to a first-in-human study is one of the most meaningful milestones in MedTech development.
It is the point where an idea begins to move beyond engineering models, bench testing, and internal design reviews—and into real clinical use.
For founders and product teams, it is also one of the most challenging transitions. The path to first-in-human is rarely defined by one breakthrough moment. It is built through a series of coordinated decisions across product development, clinical planning, regulatory strategy, risk management, manufacturing, and program execution.
A strong concept may create excitement. A well-executed development plan is what helps bring that concept to clinical validation.
What Does “First-in-Human” Mean?
A first-in-human study is generally the first time a medical device is used in people under a defined clinical protocol.
The purpose may vary depending on the device, clinical application, geography, and regulatory pathway. In many cases, the goal is to gather early clinical data related to safety, device performance, procedural workflow, usability, and technical feasibility.
For a MedTech company, this milestone can provide critical learning about:
How the device performs in a real clinical environment
Whether the intended use and clinical workflow are practical
How physicians, nurses, and other users interact with the device
What design improvements may still be needed
Whether preclinical findings translate into clinical use
What evidence will be needed for future regulatory and commercialization decisions
First-in-human work is not simply a clinical event. It is a development milestone that can influence the product, the regulatory strategy, the manufacturing plan, and the company’s next stage of growth.
The Typical Path from Concept to First-in-Human
Every device program is different, but most teams move through several connected stages before reaching first-in-human clinical use.
1. Concept Development
The development process begins with a clear understanding of the unmet clinical need.
At this stage, teams should begin defining:
The clinical problem being solved
The intended users and care setting
The desired workflow
Initial product concepts
High-level product requirements
Potential risks and technical challenges
Commercial opportunity and target market
Early concept work should involve more than internal engineering discussions. Direct input from clinicians, physicians, nurses, and other users can help the team understand where the current workflow creates friction, where existing tools fall short, and what success should look like in the clinical environment.
A strong concept is grounded in a real use case—not just a technical possibility.
2. Prototyping and Feasibility Testing
Once a concept begins to take shape, prototypes allow the team to test technical assumptions and gather feedback.
Prototypes may be used to explore:
Device geometry and ergonomics
Handle design and user interaction
Material selection
Mechanical performance
Delivery, navigation, deployment, or actuation
Compatibility with other devices or accessories
Procedure workflow
Initial usability considerations
Feasibility testing is an opportunity to learn quickly. A prototype does not need to be production-ready to provide valuable information. It does need to answer meaningful questions.
The best teams use early testing to identify what should change before the product becomes more complex, expensive, and difficult to modify.
3. Preclinical Validation and Animal Studies
For many device programs, preclinical work is an important bridge between early feasibility and clinical use.
Depending on the technology, this stage may include bench testing, simulated-use testing, cadaver studies, animal studies, anatomical models, or other preclinical evaluations.
These activities can help teams assess:
Safety and performance
Device functionality in anatomically relevant conditions
Procedural workflow
Deployment or delivery performance
Interaction with tissue or anatomy
Use-related risks
Physician feedback and training needs
Areas requiring further design iteration
Preclinical studies often generate some of the most valuable learning in the development process. They can reveal differences between a device that works in a controlled test environment and a device that performs reliably in a realistic clinical setting.
The insights gathered here should feed directly back into the product requirements, risk management file, verification strategy, usability considerations, and clinical plan.
4. Regulatory Strategy and Documentation
Regulatory planning should begin long before the first-in-human study is scheduled.
The regulatory pathway affects what testing, documentation, clinical evidence, and quality-system activities may be required before a device can be used in a clinical setting.
Early regulatory work may include:
Defining intended use and indications for use
Evaluating device classification and potential pathways
Identifying applicable standards and testing expectations
Reviewing predicate devices or comparable technologies
Developing a regulatory development plan
Planning for design controls and traceability
Establishing risk-management documentation
Identifying preclinical, usability, and clinical evidence needs
Preparing for regulatory interactions, where appropriate
A regulatory strategy is not only about preparing a submission. It helps guide development decisions so the product is being built with the required evidence in mind.
5. Manufacturing and Clinical Supply Readiness
Before first-in-human use, the team needs confidence that clinical units can be built consistently and safely.
This does not always mean full commercial-scale manufacturing. It does mean that the product, process, materials, quality controls, packaging, labeling, and supply chain are sufficiently mature to support clinical use.
Clinical supply planning may include:
Component and material sourcing
Supplier qualification
Assembly process development
Inspection methods and acceptance criteria
Process documentation
Device traceability
Packaging and sterilization planning
Labeling and instructions for use
Shipping and storage considerations
Clinical-site supply planning
Early manufacturing involvement is especially important for complex devices, catheter-based technologies, sterile disposables, implantable systems, and products with specialized materials or assembly processes.
The device used in a first-in-human study must reflect the design and manufacturing controls appropriate for the clinical stage—not simply an early engineering prototype.
Why Cross-Functional Coordination Matters
Moving from concept to first-in-human requires more than good engineering.
It requires alignment across multiple disciplines, including:
Product development and engineering
Clinical and medical affairs
Regulatory and quality
Manufacturing and operations
Supply chain and suppliers
Program management
Physicians, nurses, and clinical investigators
External testing partners and contract manufacturers
Each group contributes critical insight. Engineering may define the design. Clinicians may identify workflow needs. Regulatory teams may shape evidence requirements. Manufacturing teams may identify process constraints. Quality teams may ensure traceability and control.
Without coordination, teams can lose time when one workstream advances without considering another.
For example, a design decision may affect the sterilization approach. A clinical workflow change may alter the user-interface requirements. A supplier change may require additional testing. A late-stage manufacturing issue may impact the units available for a clinical study.
A clear program plan helps connect these decisions before they become schedule delays.
Common Challenges on the Path to First-in-Human
Many early-stage MedTech teams encounter similar challenges as they approach clinical validation.
These may include:
Unclear intended use or incomplete user needs
Product requirements that do not reflect clinical workflow
Technical feasibility proven, but manufacturability not yet considered
Insufficient preclinical data to support the clinical plan
Late regulatory engagement
Incomplete risk-management documentation
Supplier and material lead-time issues
Packaging, sterilization, or labeling decisions delayed too long
Limited clinical-unit build planning
Cross-functional teams working toward different timelines or assumptions
These challenges are manageable when they are identified early. They become much more disruptive when they are discovered immediately before a clinical milestone.
Building a More Efficient Path Forward
The companies that move efficiently toward first-in-human are not necessarily the ones that avoid iteration.
They are the ones that plan for it.
They recognize that feasibility, preclinical studies, and early clinical work will generate new learning. They create a roadmap that allows the team to respond to that learning without losing sight of the larger development and commercialization strategy.
A practical path to first-in-human should include:
Clear clinical need and intended use
Defined user needs and early product requirements
A structured prototype and feasibility plan
Preclinical and animal-study strategy
Regulatory and quality roadmap
Risk-management and design-control activities
Clinical supply and manufacturing readiness plan
Supplier, packaging, sterilization, and labeling considerations
Clinical-site and investigator coordination
Defined program milestones, risks, ownership, and decision points
Innovation creates the opportunity.
Execution brings the technology to life.
At Birch Design, we help medical device innovators connect early concepts, prototyping, preclinical work, regulatory strategy, manufacturing readiness, and clinical planning into a practical path toward first-in-human studies and commercialization.
Building a medical device and preparing for clinical validation? Birch Design helps teams bring structure, urgency, and cross-functional execution to the journey from concept to first-in-human.